Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT combined with cetuximab for oligometastatic nasopharyngeal carcinoma
ChiCTR1800015589Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in nasopharyngeal carcinoma (NPC), sponsored by West China Hospital of Sichuan University. Primary endpoint: overall survival. Started May 2018; status: recruiting.
02
Drugs
cetuximab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800015589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015589.